ArriVent BioPharma, Inc. AVBP

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

We are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. We seek to utilize our team's deep drug development experience to maximize the potential of our lead product candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, including ARR-217 (MRG007), through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. Firmonertinib is currently being evaluated in multiple clinical trials across a range of epidermal growth factor receptor (EGFR) mutations (EGFRm) in non-small cell lung cancer (NSCLC). We are conducting a pivotal Phase 3 clinical trial of firmonertinib in treatment naive, or first-line, patients with locally advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations and a pivotal Phase 3 clinical trial of firmonertinib in first-line patients with locally advanced or metastatic EGFRm NSCLC with P-loop and-alpha-c-helix compressing (PACC) mutations. We are conducting a Phase 1 clinical trial of ARR-217 in patients with unresectable locally advanced or metastatic solid tumors.

Last close 21.00 2026-10-23
Market cap $1.04B 2026-06-30 share count
52-week range 11.36 - 35.83

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-4.32

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022
R&D $153.4M$79.0M$64.9M—
SG&A $24.2M$15.3M$9.7M—
Total operating expenses $177.5M$94.3M$74.6M—
Operating income -$177.5M-$94.3M-$74.6M—
Net income -$166.3M-$80.5M-$69.3M—
EPS, basic -4.32-2.56-32.38—
EPS, diluted -4.32-2.56-32.38—
Shares, diluted (wtd. avg.) 38.5M31.5M2.1M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022
Cash and equivalents $45.5M$74.3M$150.4M$163.4M
Short-term investments $267.3M$144.6M——
Total current assets $332.9M$227.0M$160.0M—
Total assets $333.2M$274.9M$163.1M—
Accounts payable $5.9M$3.8M$4.5M—
Total current liabilities $25.9M$17.3M$11.6M—
Total liabilities $25.9M$17.3M$11.8M—
Retained earnings -$404.6M-$238.3M-$157.8M—
Total equity $307.2M$257.7M-$153.2M-$85.1M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022
Operating cash flow -$160.6M-$70.2M-$55.8M—
Depreciation and amortisation -$3.0M———
Stock-based compensation $12.5M$3.2M$895.0K—
Investing cash flow -$71.2M-$192.5M——
Financing cash flow $203.1M$186.6M$42.9M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-024127.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -200M -150M -100M -50M 0 Net income, FY2023: -69.3M Net income, FY2024: -80.5M Net income, FY2025: -166.3M FY2022 FY2023 FY2024 FY2025
Fiscal year FY2022FY2023FY2024FY2025
Revenue — — — —
Gross profit — — — —
Net income — -$69.3M -$80.5M -$166.3M

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%